PRRX1 and breast carcinoma: Currently available reports have tried to explain RBMS3′s anticancer activity in all types of breast cancer through the inhibition of the Wnt/β-catenin pathway and the inhibition of the epithelial–mesenchymal transition process (EMT), mainly by impacting on TWIST, PRRX1, or MMP2 [14,17,19].